20-Mar-2026
Lantheus says FDA extended review period for radioactive diagnostic kit
Seeking Alpha News (Wed, 18-Mar 11:43 AM ET)
TipRanks (Wed, 18-Mar 7:50 AM ET)
Globe Newswire (Tue, 17-Mar 4:01 PM ET)
Lantheus Announces FDA Approval of PYLARIFY TruVu (piflufolastat F 18) Injection
Globe Newswire (Fri, 6-Mar 4:01 PM ET)
Business Wire (Mon, 2-Mar 12:19 PM ET)
Globe Newswire (Mon, 2-Mar 8:30 AM ET)
Lantheus Narrows Focus on Radiodiagnostics After Reporting $1.54 Billion in 2025 Revenue
Market Chameleon (Thu, 26-Feb 3:36 AM ET)
Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Globe Newswire (Thu, 26-Feb 7:00 AM ET)
Globe Newswire (Thu, 12-Feb 8:00 AM ET)
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Lantheus Holdings trades on the NASDAQ stock market under the symbol LNTH.
As of March 20, 2026, LNTH stock price declined to $76.43 with 1,619,160 million shares trading.
LNTH has a beta of 0.74, meaning it tends to be less sensitive to market movements. LNTH has a correlation of 0.06 to the broad based SPY ETF.
LNTH has a market cap of $5.07 billion. This is considered a Mid Cap stock.
Last quarter Lantheus Holdings reported $407 million in Revenue and $1.67 earnings per share. This beat revenue expectation by $39 million and exceeded earnings estimates by $.59.
In the last 3 years, LNTH traded as high as $126.89 and as low as $47.25.
The top ETF exchange traded funds that LNTH belongs to (by Net Assets): IJH, VTI, IWM, VB, AVUV.
LNTH has underperformed the market in the last year with a return of -22.7%, while SPY returned +16.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in LNTH shares. However, LNTH has outperformed the market in the last 3 month and 2 week periods, returning +15.9% and +5.3%, while SPY returned -4.4% and -3.3%, respectively. This indicates LNTH has been having a stronger performance recently.
LNTH support price is $75.52 and resistance is $80.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LNTH shares will trade within this expected range on the day.